Literature DB >> 18601707

Gut hormones: a weight off your mind.

J V Gardiner1, C N Jayasena, S R Bloom.   

Abstract

The increasing prevalence of obesity and the associated morbidity and mortality has resulted in a major research effort to identify mechanisms that regulate appetite. It is well established that the hypothalamus and brain stem are major sites in the central nervous system (CNS) that regulate appetite. Until recently the missing element has been how information regarding food intake and energy stores is communicated to the CNS. Gut hormones have recently been found to be an important element in this regulation, communicating information regarding food intake to the CNS. Several gut hormones have been found to exert anorectic effects. These include members of the Pancreatic Polypeptide (PP)-fold family, namely PP itself and also peptide tyrosine-tyrosine (PYY), the first gut hormone shown to have appetite-inhibiting properties. The other main class of anorectic gut hormones are those derived by proteolytic processing from proglucagon, most importantly glucagon-like peptide-1 (GLP-1) and oxyntomodulin. All of these are currently being investigated as the basis of treatments to prevent the development of obesity. So far the only gastrointestinal hormone demonstrated to stimulate appetite is ghrelin. Potential sites and mechanisms of action and therapeutic use of these gastrointestinal hormones are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18601707     DOI: 10.1111/j.1365-2826.2008.01729.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  12 in total

Review 1.  Secretin: Should we revisit its metabolic outcomes?

Authors:  D H St-Pierre; F Broglio
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

2.  Circulating ghrelin and GLP-1 are not affected by habitual diet.

Authors:  Amy C Ellis; Paula Chandler-Laney; Krista Casazza; Laura Lee Goree; Gerald McGwin; Barbara A Gower
Journal:  Regul Pept       Date:  2012-02-28

Review 3.  Recent advances in clinical practice challenges and opportunities in the management of obesity.

Authors:  Andres Acosta; Barham K Abu Dayyeh; John D Port; Michael Camilleri
Journal:  Gut       Date:  2014-01-08       Impact factor: 23.059

Review 4.  Nesfatin-1: a novel inhibitory regulator of food intake and body weight.

Authors:  A Stengel; M Goebel; Y Taché
Journal:  Obes Rev       Date:  2011-04       Impact factor: 9.213

Review 5.  Nesfatin-1--role as possible new potent regulator of food intake.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Regul Pept       Date:  2010-05-16

6.  Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses.

Authors:  Helen M Cox; Iain R Tough; Anne-Marie Woolston; Lei Zhang; Amy D Nguyen; Amanda Sainsbury; Herbert Herzog
Journal:  Cell Metab       Date:  2010-06-09       Impact factor: 27.287

7.  Resistin-like molecule alpha decreases glucose tolerance during intestinal inflammation.

Authors:  Ariel Munitz; Luqman Seidu; Eric T Cole; Richard Ahrens; Simon P Hogan; Marc E Rothenberg
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 8.  Therapeutic potential of neuropeptide Y (NPY) receptor ligands.

Authors:  Shaun P Brothers; Claes Wahlestedt
Journal:  EMBO Mol Med       Date:  2010-11       Impact factor: 12.137

9.  Duration of lactation and maternal adipokines at 3 years postpartum.

Authors:  Alison M Stuebe; Christos Mantzoros; Ken Kleinman; Matthew W Gillman; Sheryl Rifas-Shiman; Erica P Gunderson; Janet Rich-Edwards
Journal:  Diabetes       Date:  2011-02-24       Impact factor: 9.461

Review 10.  Cross-talk in the gut.

Authors:  Jennifer E Dinalo; David A Relman
Journal:  Genome Biol       Date:  2009-01-23       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.